Pay in 4 interest-free payments of $6.33 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
doi:10.1080/10408398.2018.1511967
A consultation with one of our expert healthcare providers is needed to examine your medical history and discuss your weight loss goals to determine whether GLP-1 weight management is right for you
Stacking considerations: DSIP combines reasonably well with certain other peptides and supplements, though caution is warranted
Key Takeaways Triple agonist mechanism: Retatrutide is the first medication to activate GIP, GLP-1, and glucagon receptors simultaneously GLP-1 component reduces appetite and slows gastric emptying, the core appetite suppression pathway GIP component improves insulin sensitivity and promotes favorable fat distribution Glucagon component increases energy expenditure through thermogenesis and promotes fat breakdown Weight loss: Phase 2 trials showed up to 24.2% weight loss at 48 weeks, compared to tirzepatide (~22%) and semaglutide (~15%) Investigational status: Not FDA-approved
Set up in 1987 in San Diego, Amylin was a small biotechnology company already developing another diabetic drug and agreed to take the gamble with Raufman and Eng's peptide
Referenced Citations Reconstitution of Medications
US$ 25.37
US$ 21.04
US$ 23.16
US$ 21.55
US$ 23.26
US$ 26.09
US$ 25.61
US$ 22.33
US$ 21.31
US$ 29.65
US$ 21.33
US$ 29.80
